Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover.
about
Targeting DNA Replication Stress for Cancer TherapyGenetically engineered mouse models for functional studies of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligasesUbiquitylation, neddylation and the DNA damage responseThe tail that wags the dog: p12, the smallest subunit of DNA polymerase δ, is degraded by ubiquitin ligases in response to DNA damage and during cell cycle progressionMutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cellsNEDDylation is essential for Kaposi's sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV targetDistinct outcomes of CRL-Nedd8 pathway inhibition reveal cancer cell plasticityInactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis.Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinomaHistone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Protein neddylation: beyond cullin-RING ligases.Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsThe stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase.Neddylation pathway is up-regulated in human intrahepatic cholangiocarcinoma and serves as a potential therapeutic targetPevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.Neddylation promotes ubiquitylation and release of Ku from DNA-damage sites.Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapyThe NEDD8-activating enzyme inhibitor MLN4924 disrupts nucleotide metabolism and augments the efficacy of cytarabineMechanism of CRL4(Cdt2), a PCNA-dependent E3 ubiquitin ligaseUncovering ubiquitin and ubiquitin-like signaling networks.Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor.Rational Combinations of Targeted Agents in AMLSynergistic inhibition of autophagy and neddylation pathways as a novel therapeutic approach for targeting liver cancer.Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic applicationTargeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.Activation of MAPK/ERK signaling by Burkholderia pseudomallei cycle inhibiting factor (Cif).Targeting neddylation induces DNA damage and checkpoint activation and sensitizes chronic lymphocytic leukemia B cells to alkylating agentsRe-replication induced by geminin depletion occurs from G2 and is enhanced by checkpoint activation.The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.Geminin deploys multiple mechanisms to regulate Cdt1 before cell division thus ensuring the proper execution of DNA replication.The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemiaInitial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.Suppression of tumor angiogenesis by targeting the protein neddylation pathway.
P2860
Q26739923-BE1AE638-EC9D-4B47-A642-3A2DF22F79ACQ27027897-8CE3F33F-E5D9-4E6B-8066-6F8D7F9BC12DQ28087342-1F5D8DF6-4E46-48AA-A8F8-07385C8A736DQ28303222-130850E1-123C-456F-96D4-E52BB0A96779Q28541763-3D228A05-8EB7-42D2-97B3-E5218649988FQ28544735-8CB81AF8-2E52-4C3D-969B-E0AEB22F8527Q28818350-3AC025C9-FF5B-4146-9CD8-A9747BF04946Q30276526-E576CC4C-9D75-46BD-9D06-35F510F5788EQ30525356-213C3051-5AE4-4D22-8DA1-888526D091E3Q33427510-CBDDD86D-9B9B-4C49-A1B1-7C3D1FBCAB0EQ33714747-2E73CFA8-E762-4A0E-83C1-182C2FD9D99AQ33912016-D3EBB808-8337-4136-83F6-1ECA6F5CA393Q33983255-BE5B355D-4A83-4F4C-B136-AF7C5CF49726Q34042816-AF8979FE-0E4C-4607-9BDF-3A6A448ECC82Q34043821-C743619F-4E2E-45D8-B1DF-3614328E3E2AQ34218976-955011D0-7E44-4217-95BB-B70800A8635DQ34227548-5B11E2E9-B649-48D1-83F4-F0508031CF70Q34365897-F37EA1AE-8A4F-4FA9-9426-8D180CB4F144Q34465347-D28A4D34-1E3C-4C02-8A6E-39BBA8E0C081Q34474077-A9F5F3C6-5330-48EE-A598-6A6A8184A34AQ34476246-2727F147-63C6-40C9-AF12-DA2B59F8EB2EQ34521260-3DE3E2D3-39FD-458D-B941-BCA3E95DB715Q34563129-2AC52162-E65B-42A9-B7BA-DD0E5715BFAEQ34979606-AA5FEB28-C41D-47EB-982D-A88DE7E7A454Q35237385-CBD5F488-5481-4D68-9B13-E89C116FD3CCQ35615172-5B1CCFBD-7059-4F9F-B6CD-D8D0D79F7A5EQ35653286-4EEBF2AF-6A19-40E9-8057-2556F0DF859EQ35750491-1706F2A1-341F-4231-89E1-CAE74041271AQ35832285-F65EF7ED-CC41-4047-B055-31D379AF3123Q36062128-5C702895-E2B9-4019-896A-54800EBD9F39Q36215406-71AF0844-F01B-4BD1-8093-90D9ECF45F78Q36271721-B01ED858-9926-4139-BF96-8EB26F37AB10Q36293814-A03A1651-B2F8-4AD7-B0A7-3A04B38E2D16Q36348378-FC40AF4B-BE71-4279-9539-945A22168AC2Q36876973-3675306A-60EC-4C81-B7DD-1AC3D25F1A36Q37049530-4E91FED0-39F8-4D41-8BB5-4AD9EBF93F40Q37269140-D3043F41-1560-4A9D-A4F0-2ECD17F1C16EQ37295143-1C501F00-A84F-405E-902F-608B29B7739EQ37388126-4EA73C85-D339-4531-95B5-BB46D62A13BBQ37620640-DBE42E39-F918-43D5-AADD-7DCA0AE4FB29
P2860
Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Inhibition of NEDD8-activating ...... th deregulating CDT1 turnover.
@en
Inhibition of NEDD8-activating ...... th deregulating CDT1 turnover.
@nl
type
label
Inhibition of NEDD8-activating ...... th deregulating CDT1 turnover.
@en
Inhibition of NEDD8-activating ...... th deregulating CDT1 turnover.
@nl
prefLabel
Inhibition of NEDD8-activating ...... th deregulating CDT1 turnover.
@en
Inhibition of NEDD8-activating ...... th deregulating CDT1 turnover.
@nl
P2093
P1433
P1476
Inhibition of NEDD8-activating ...... th deregulating CDT1 turnover.
@en
P2093
Benjamin Amidon
Michael A Milhollen
Peter G Smith
Petter O Veiby
Teresa A Soucy
Usha Narayanan
P304
P356
10.1158/0008-5472.CAN-10-2122
P407
P577
2011-04-12T00:00:00Z